NCT05984017招募中不适用
A Non-interventional Study and Its Clinical Relevance With Advanced Lung Squamous Cell Carcinoma
Hunan Province Tumor Hospital1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2021年7月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 130
- 试验地点
- 1
- 主要终点
- progression-free survival
研究概览
简要总结
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be ≥18 years.
- •Provision of fully informed consent prior to any study specific procedures.
- •Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
- •According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
排除标准
- 未提供
结局指标
主要结局
progression-free survival
时间窗: 2 years
From registration onto that step until death, or censored at the date of last contact.
Overall survival
时间窗: 2 years
From registration onto that step until death, or censored at the date of last contact.
次要结局
未报告次要终点
研究者
Yongchang Zhang
Professor, Deputy Director of Thoracic Oncology Department
Hunan Province Tumor Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung CancerNSCLCNCT05991193Hunan Province Tumor Hospital100
已完成
不适用
Study to Assess Iron Chelation Therapy in Patients With Chronic Iron OverloadChronic Iron OverloadNCT05440487Novartis Pharmaceuticals489
已完成
不适用
Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With BicalutamideAdvanced Prostate CancerNCT00871585AstraZeneca340
招募中
不适用
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United KingdomChronic Lymphocytic Leukemia, CLLNCT05557695AstraZeneca287
招募中
不适用
A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally AdvancedNSCLC, Stage IIINSCLC, Stage INon-small Cell Lung CancerNSCLCNCT06467383MSD Italia S.r.l.600